Biotech Drug Report Generated Jul 1, 2026

atumelnant

CRNX·Crinetics Pharmaceuticals, Inc.

BULLISH

Drug Impact Rating6/10

Trial Phase: Phase 3 (CAH); Phase 1b/2a (ADCS)
Time to Market: Estimated 2028 for CAH if Phase 3 succeeds (assuming ~1.5-2 year Phase 3 enrollment + regulatory review); ADCS indication is earlier-stage.
Why 6/10: The next hard catalyst is the Phase 3 CALM-CAH topline readout (pivotal trial started Dec 2025; estimated conclusion late 2026 to early 2027). Atumelnant is a major pipeline driver but Crinetics also has PALSONIFY approved and generating commercial revenue, so it's not a pure single-asset binary.

Actionable Insight BULLISH

Watch for CALM-CAH enrollment completion updates and any topline readout timeline guidance on upcoming quarterly earnings calls. The Phase 3 data is the make-or-break event, but the stock already has a commercial-stage floor from PALSONIFY revenue, reducing doomsday downside. Competitor Neurocrine's CRENESSITY is approved first, but early data suggests atumelnant may have a superior efficacy profile.

Price Chart

Loading chart...

Executive Summary

Atumelnant (CRN04894) is Crinetics' second pipeline drug — a first-in-class, once-daily oral ACTH receptor antagonist in late-stage development for congenital adrenal hyperplasia (CAH) and early-stage for ACTH-dependent Cushing's syndrome. Phase 2 data showed rapid, sustained reductions in disease biomarkers (up to 80% reduction in androstenedione) and normalized steroid dosing in 88% of patients. A pivotal Phase 3 trial (CALM-CAH) began enrollment in December 2025. Atumelnant faces competition from Neurocrine's already-approved CRENESSITY (crinecerfont), but early comparisons suggest a potential efficacy advantage. Crinetics already has one commercial product (PALSONIFY for acromegaly, $10.3M Q1 2026 revenue), providing a revenue base and reducing single-point-of-failure risk. Analyst consensus is Strong Buy with a mean price target implying ~123% upside.

How It Works

Atumelnant is a once-daily pill that blocks the ACTH hormone from binding to its receptor (MC2R) on the adrenal glands. In CAH and certain forms of Cushing's syndrome, the body makes too much ACTH, causing the adrenal glands to overproduce androgens and cortisol. By blocking ACTH at the source, atumelnant aims to normalize hormone levels without high-dose steroids.

Trial Status

Phase 2 TouCAHn in classic CAH completed with positive results (presented at ENDO June 2026). Phase 3 CALM-CAH (adult CAH, double-blind placebo-controlled) began dosing December 2025, actively enrolling globally. Phase 2/3 BALANCE-CAH (pediatric CAH) began January 2026. Phase 1b/2a in ACTH-dependent Cushing's syndrome (ADCS) is enrolling with interim data presented at ENDO 2026.

The Two-Sided Case

▲ Bull Case6

Phase 2 data showed up to 80% mean reduction in androstenedione and normalization of glucocorticoid dosing in 88% of patients, suggesting best-in-class potential vs Neurocrine's approved CRENESSITY (source: Crinetics press release, Jan 2025)

FDA granted Orphan Drug Designation for CAH in August 2025, providing 7-year market exclusivity, fee waivers, and tax credits (source: FDA/HCPLive)

Analyst consensus is Strong Buy (20 buy/strong buy vs 2 hold) with a mean price target of $83.14, implying ~123% upside from $37.42

Crinetics already has PALSONIFY approved and commercialized ($10.3M Q1 2026 revenue), providing a commercial infrastructure and reducing reliance on atumelnant as the sole value driver (source: Crinetics Q1 2026 earnings)

Major institutional holders include FMR (Fidelity) with ~$665M, Vanguard, and BlackRock; Baker Bros. Advisors added 42.6% in Q1 2026 (source: SEC 13F filings)

Goldman Sachs upgraded CRNX from Neutral to Buy in January 2026, and multiple top-tier analyst firms rate it Outperform

▼ Bear Case6

Neurocrine's CRENESSITY (crinecerfont) is already FDA-approved for CAH (adults and children ages 4+), giving it significant first-mover advantage and established prescriber relationships (source: FDA press release)

Phase 2 TouCAHn was open-label with no placebo control, limiting the reliability of efficacy claims until Phase 3 data is available (source: ClinicalTrials.gov NCT05907291)

Phase 3 CALM-CAH enrollment only began December 2025; topline readout is likely late 2026 to early 2027 at the earliest, leaving a binary risk overhang for months (source: Crinetics press release)

Insider selling detected: multiple executives sold shares in early 2026, including Jeff Knight (85K shares at ~$40) and the CEO Richard Struthers (13K shares at $37) (source: SEC Form 4 filings)

Point72, Balyasny, and Neuberger Berman exited or nearly exited CRNX positions in Q1 2026, signaling some institutional caution (source: 13F filings)

Crinetics is not yet profitable (Q1 2026 EPS of -$1.23, missing estimates), and continued R&D spend on multiple trials could require future dilution (source: TipRanks)

Upcoming Catalysts

Phase 3 CALM-CAH topline readout (estimated late 2026 to early 2027)
Phase 2/3 BALANCE-CAH pediatric CAH trial enrollment and interim data
Phase 1b/2a ADCS (Cushing's syndrome) data updates
Quarterly earnings calls with pipeline timeline updates
Potential regulatory filing for PALSONIFY in additional geographies (Japan, etc.)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Crinetics Pharmaceuticals, Inc. PRESS-RELEASE CRNX ·Originating report

Sources · 13

Hover a chip for the title

1 en.wikipedia.org2 crinetics.com3 crinetics.com4 crinetics.com5 crinetics.com6 hcplive.com7 biospace.com8 techtimes.com9 crinetics.com10 clinicaltrials.gov11 tipranks.com12 fda.gov13 pmc.ncbi.nlm.nih.gov